Heart Transplant with Donor-Specific Antibody after Immunoadsorption plus Rituximab: A Case Report

Abstract

Different desensitization strategies are available for treating patients with preformed human leukocyte antigen (HLA) antibodies. A highly presensitized heart recipient received immunoadsorption and rituximab therapy. The patient, with end-stage heart failure, was positive only for antibodies of HLA class I (anti-A2, A10, B17), and Luminex platform (One Lambda kit) showed a panel-reactive antibody score of 64%. The patient's serum was tested repeatedly in both complement-dependent cytotoxicity and flow-cytometry crossmatches against cells from different potential organ donors. The results of these crossmatches were positive on flow cytometry when tested with HLA-A2, A10, and B17 but were still negative on cytotoxicity. The patient was treated with a desensitization regimen; this treatment immediately decreased antibody levels of 70% and the patient subsequently received a transplant with donor-specific HLA antibody (HLA-A2). After more than 2 years, graft function remains normal and the clinical status of the patient is stable.

Get full access to this article

View all access options for this article.

References

Vlad

Vasilescu

. Pre-and post-transplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Hum Immunol. 2011;72(1):5–10.

Picascia

Grimaldi

Zullo

. Current concepts in histocompatibility during heart transplant. Exp Clin Transplant. 2012;10(3):209–218.

Velez

Johnson

. Management of allosensitized cardiac transplant candidates. Transplant Rev (Orlando). 2009;23(4): 235–247.

Asante-Korang

Jacobs

Ringewald

. Management of children undergoing cardiac transplantation with high panel reactive antibodies. Cardiol Young. 2011;21(suppl 2):124–132.

Minucci

Grimaldi

Casamassimi

. Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: A comparative study. Exp Clin Transplant. 2011; 9(6):381–386.

Glotz

Antoine

Duboust

. Antidonor antibodies and transplantation: How to deal with them before and after transplantation. Transplantation. 2005;79(3 suppl):S30–S32.

Crudele

Picascia

Infante

Grimaldi

Maiello

Napoli

. Repeated immune and non immune insults to the graft after heart transplantation. Immunol Lett. 2011;141(1): 18–27.

Kittleson

Kobashigawa

. Management of advanced heart failure: The role of heart transplantation. Circulation. 2011;123(14):1569–1574.

Pescovitz

. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant. 2006;6(5 pt 1):859–866.

10.

Delgado

Eckels

. Positive B-cell only flow cytometric crossmatch: Implications for renal transplantation. Exp Mol Pathol. 2008;85(1):59–63.

11.

Nwakanma

Williams

Weiss

Russell

Baumgartner

Conte

. Influence of pre-transplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007;84(5):1556–1562; discussion 1562–1563.

12.

Aubert

Venetz

Pantaleo

Pascual

. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol. 2009;70(8):580–583.

13.

Roelen

Doxiadis II Claas

. Detection and clinical relevance of donor specific HLA antibodies: A matter of debate. Transpl Int. 2012;25(6):604–610.

14.

Pollock-BarZiv

Den Hollander

Ngan

. Pediatric heart transplantation in human leukocyte antigen sensitized patients: Evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation. 2007;116(11 suppl):I172–I178.

15.

Kaczmarek

Deutsch

Sadoni

. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: Case report and literature review. J Heart Lung Transplant. 2007;26(5):511–515.

16.

Keren

Hayes

O'Driscoll

. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab. Transplant Proc. 2006;38(5): 1520–1522.

17.

Vieira

Agarwal

Book

. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77(4):542–548.

18.

Lukovsky

Toyoda

. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242–251.

19.

Bućin

Gustafsson

Ekmehag

. Desensitization and heart transplantation of a patient with high levels of donor-reactive anti-human leukocyte antigen antibodies. Transplantation. 2010;90(11):1220–1225.